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.2011.11.0Abstract Hydrodynamically balanced systems (HBSs) of oﬂoxacin were prepared using lactose,
HPMC K4M, PVP K 30, and liquid parafﬁn, which may increase the mean residence time in the
gastrointestinal tract, and may be able to provide maximum drug at the site of absorption to
improve oral bioavailability. All these formulated HBS capsules were ﬂoated well over 6 h with
no ﬂoating lag time. They also showed sustained drug release over 6 h. Time for 50% release of
oﬂoxacin was within the range, 2.47 ± 0.02 to 3.07 ± 0.08 h. The in vitro drug release from these
HBS capsules was dependent on HPMC K4M, PVP K 30, and liquid parafﬁn content. The drug
release pattern of these HBS capsules containing oﬂoxacin followed the Higuchi model with the
anomalous transport mechanism.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Oral controlled-release drug delivery technology represents
one of the frontier areas of science, involving multidisciplinary
scientiﬁc approaches that all contribute to human healthcare.
The challenge in the development of oral controlled-release
drug delivery systems is not just to sustain the drug release,
but also to prolong the gastric residence of dosage forms until
all the drug is completely released at the desired period
(Tadros, 2010). Prolonged gastric residence increases duration83131603.
o.in (A.K. Nayak).
Saud University.
g by Elsevier
. Production and hosting by Elsev
02of drug release, and reduces drug waste with improved bio-
availability (Garg and Gupta, 2008; Nayak et al., 2010b;
Nayak et al., 2010c). Apart from these advantages, gastric res-
idence of dosage forms offer various pharmacokinetic advan-
tages like maintenance of constant therapeutic levels over a
prolonged period, and thus, reduction in ﬂuctuation in thera-
peutic levels minimizing the risk of resistance especially in
the case of antibiotics. Over the past few decades, several gas-
troretentive drug delivery approaches are being designed and
developed, including ﬂoatation (Sing and Kim, 2000; Arrora
et al. 2005), mucoadhesion (Chowdary and Rao, 2004; Nayak
et al., 2010a), sedimentation (Rouge et al. 1998), unfoldable,
expandable, or swellable systems (Klausner et al., 2003), super-
porous hydrogel systems (Chen et al., 2000), magnetic systems
(Fujimori et al., 1994) etc. Among them, ﬂoating drug delivery
presents a number of applications for drugs having poor bio-
availability because of the narrow absorption window in the
upper part of gastrointestinal tract. It retains the dosage formier B.V. All rights reserved.
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(Ali et al., 2007).
Oﬂoxacin (9-ﬂuoro-2, 3-dihydro-3-methyl-10 (4-methyl-1-
piperazinyl)-7-oxo-7H pyrido [1,2,3-de]-1,4-benzoxazine-6-car-
boxylic acid) is a synthetic ﬂuroquinolone derivative, which acts
by inhibiting the topoisomerase enzyme which is essential in the
reproduction of the bacterial DNA (Tripathy, 2003). Oﬂoxacin
is highly sensitive to both Gram-positive and Gram-negative
bacteria. It is also active against mycoplasma, chlamydia and
legionella. While widely used to treat infections, such as those
affecting the gastrointestinal and respiratory tracts, it is also
used to treat urinary tract infections (Zivanovic et al., 2006;
Cui et al., 2008). It is highly soluble in acidic media and precip-
itates in alkaline media thereby losing its solubility. Hence, gas-
troretentive ﬂoating systems of oﬂoaxcin should enhance the
bioavailability by retaining it in the acidic environment of the
stomach. Few investigations have also been carried out to devel-
op and evaluate gastroretentive ﬂoating systems of oﬂoaxcin
(Janardhan et al., 2009; Semalty et al., 2010).
Among various gastroretentive ﬂoating systems, hydrody-
namically balanced systems (HBSs) are able to improve absorp-
tion of drugs especially those that are absorbed from stomach
and small intestine (Seth and Tossounian, 1984; Sahni et al.,
2006).HBSs contain drugwith gel-forming hydrocolloidsmeant
to remain buoyant in the stomach content. They are mainly sin-
gle-unit dosage forms, and are usually composed of one or more
gel-forming hydrophilic polymeric substances and an active
pharmaceutical ingredient (Dorozynski et al., 2007). Various
gastroretentive HBSs for some drug candidates have already
been investigated (Sahni et al., 2006; Ali et al. 2007; Dorozynski
et al., 2007; Salunke et al., 2009; Wason and Nanda, 2009;
Wamorkar et al., 2010). Ali et al. have investigated oﬂoxacin
HBS capsules for gastroretentive delivery using HPMC and
polyethylene oxide (Ali et al., 2006). In the present investigation,
we have planned to developHBS capsules of oﬂoxacin using lac-
tose, hydroxypropyl methylcellulose (HPMC K4M), polyvinyl
pyrrolidone (PVP K 30), and liquid parafﬁn for better delivery
of oﬂoxacin. These HBS capsules of oﬂoxacin would remain
buoyant on the gastric ﬂuid for a prolonged period and the drug
would be available in the dissolved form at the main site of its
absorption, which leads to improved bioavailability of the drug.
2. Materials and methods
2.1. Materials
Oﬂoxacin (Klar Sehen Pvt. Ltd., India), hydroxypropyl meth-
ylcellulose K4M (Central Drug House, India), liquid parafﬁn
(light, 25–80 mPa viscosity at 20 C) (Nice Chemicals Pvt.
Ltd., India), polyvinyl pyrrolidone K 30 and lactose (Loboche-
mie, India) were used. All other chemicals and reagents used
were of analytical grade.
2.2. Preparation of oﬂoxacin HBS capsules
Oﬂoxacin HBS capsules were prepared by simple blending of
100 mg of oﬂoxacin, with lactose and different polymers like
HPMC K4M, PVP K 30, and liquid parafﬁn. Magnesium stea-
rate as lubricating agent was added to the blend and mixed for
additional 3 min. Solid ﬁlling was done to ﬁll the ﬁnal blend
above components into empty hard gelatin capsules (size 0)manually. Care was taken to ﬁll the contents completely to
maintain the uniformity of contents and weight. The composi-
tion of oﬂoxacin HBS capsules is given in Table 1.
2.3. Evaluation of in vitro ﬂoating properties
The HBS capsules were immersed in 900 ml of 0.1 N HCl, pH
1.2 in USP type II apparatus at 50 rpm maintained at
37 ± 5 C for 6 h. The time for which the capsules constantly
remain aﬂoat on the surface of the medium (buoyant) was ob-
served visually and was taken as the ﬂoating time.
2.4. In vitro drug release studies
In vitro drug release studies were carried in USP type II appara-
tus at 50 rpm maintained at 37 ± 5 C. A single HBS capsule
was transferred into the dissolution medium of 900 ml of
0.1 N HCl, pH 1.2. Then 5 ml of aliquots was withdrawn from
the dissolution vessel at speciﬁc time intervals and replaced with
equivalent volume of fresh medium. Collected dissolution sam-
ples were ﬁltered using Whatmann ﬁlter (Grade I) paper and
then, used for determination of released oﬂoxacin concentra-
tions by using a UV–vis spectrophotometer (U.V. 2440 Double
beam spectrophotometer, SHIMADZU Corporation, Japan)
against a blank. Maximum wavelength (kmax) was obtained by
scanning all samples from 200 to 400 nm and this was 291 nm.
Three repetitions were done for each formulation.
2.5. Drug release kinetics
The in vitro drug release data from variousHBS capsules were evalu-
ated kinetically in various mathematical models like zero order, ﬁrst
order, Higuchi, and Korsmeyer–Peppas models (Higuchi, 1961;
Korsmeyer et al., 1983;Mulye and Turco, 1996; Varelas et al., 1995).
Zero-order Model: F= K0 t, where F represents the frac-
tion of drug released in time t, and KO is the apparent release
rate constant or zero-order release constant.
First-order Model: ln (1F) = K1st t, where F represents
the fraction of drug released in time t, and K1 is the ﬁrst-order
release constant.
Higuchi Model: F=KH t
½, where F represents the fraction of
drug released in time t, and KH is the Higuchi dissolution constant.
Korsmeyer–Peppas Model: F= KP t
n, where F represents
the fraction of drug released in time t, KP is the rate constant
and n is the diffusional exponent, this indicates the drug re-
lease mechanism.
2.6. Statistical analysis
The time for 50% release of oﬂoxacin from HBS capsules was
analyzed for signiﬁcant differences by one-way analysis of var-
iance (ANOVA) using a Student-Newman-Keuls test for all
pair wise comparisons in this study. The statistical analysis
was conducted using MedCalc software version 9.6.4.0.
3. Results and discussion
All these HBS capsules containing oﬂoxacin were ﬂoated well
with no ﬂoating lag time. The ﬂoating time of these oﬂoxacin
HBS capsules wasmore than 6 h (Fig. 1). Thismay be accounted
Table 1 Composition of various HBS oﬂoxacin capsules.a
Formulation codes Components (mg)
Oﬂoxacin Lactose HPMC K4MK4M PVP K 30 Liquid paraﬃn Magnesium stearate
F 1 100 45 100 – – 5
F 2 100 45 80 20 – 5
F 3 100 45 80 – 20 5
F 4 100 45 80 10 10 5
a Solid ﬁlling was done for ﬁlling above components in capsules.
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with drug in the form ofHBS capsules. Themechanism involved
in buoyancy of these HBS capsules, could be rapid hydration
and swelling of the polymericmatrices producing a ﬂoatingmass
in the gastric pH (1.2). The matrix integrity of these HBS cap-
sules was satisfactory.
In vitro drug release studies were carried out in 0.1 N HCl,
pH 1.2, as dissolution medium. All these HBS oﬂoxacin cap-
sules showed sustained drug release over 6 h (Fig. 2). Time
for 50% release of oﬂoxacin from HBS capsules was calculated
from the plot of percentage drug release vs. time and presented
in Table 2. Time for 50% release of oﬂoxacin was higher
(3.27 ± 0.04 h) in the case of HBS capsules of formulation F
3, whereas this was lower (2.47 ± 0.02 h) in the case of HBS
capsules of formulation F 2. There were signiﬁcant differences
(p< 0.05) in the time for 50% release of oﬂoxacin from HBS
capsules. As HPMC K4M content in HBS capsules was
increased, the drug release rate from HBS capsules wasFigure 1 Floating behavior of HBS oﬂoxasustained and vice-versa. The higher viscosity due to higher
content of HPMC K4M may promote the formation of highly
viscous gels upon contact with aqueous ﬂuids. This would
retard the drug release rate from these HBS oﬂoxacin capsules
containing higher HPMC K4M content. In a parallel line,
Siepmann and Peppas (Siepmann and Peppas, 2001) suggested
that the drug release from HPMC matrices is sequentially gov-
erned as follows: (i) At the beginning, steep water concentra-
tion gradients are formed at the polymer/water interface
resulting in water imbibition into the matrix; (ii) Due to the
imbibition of water, HPMC swells resulting in dramatic
changes of polymer, drug concentrations and increasing
dimensions of the system; (iii) Upon contact with water, the
drug dissolves and diffuses out of the device due to concentra-
tion gradient; and (iv) With increasing water content, the dif-
fusion coefﬁcient of the drug increases substantially.
Oﬂoxacin capsules containing PVP K 30 showed higher drug
release rates than other formulations; whereas, liquid parafﬁncin capsules (F 4) in 0.1 N HCl, pH 1.2.
Figure 2 In vitro oﬂoxacin release from various HBS capsules in
0.1 N HCl, pH 1.2 (Mean ± SD).
Table 2 Times for 50% release of oﬂoxacin from HBS
capsules in 0.1 N HCl (pH 1.2), calculated from the plot of
percentage drug release vs. time.
Formulation codes Times for 50% release of oﬂoxacin
from HBS capsules (h) a,b
F 1 2.89 ± 0.02
F 2 2.47 ± 0.02
F 3 3.27 ± 0.04
F 4 3.07 ± 0.08
a Mean ± SD.
b Values were signiﬁcantly different from each other. Statistically
signiﬁcance (p< 0.05) compared with all formulations was deter-
mined by one-way ANOVA followed by using Student-Newman-
Keuls test for all pair wise comparisons.
Table 3 Results of curve ﬁtting of the in vitro oﬂoxacin release
data in 0.1 N HCl (pH 1.2) from different HBS capsules.
Formulation codes Correlation coeﬃcient (R2) values
F 1 F 2 F 3 F 4
Zero order Model 0.9848 0.9854 0.9920 0.9849
First order Model 0.9871 0.9791 0.9746 0.9818
Higuchi Model 0.9962 0.9942 0.9951 0.9949
Korsmeyer-Peppas Model 0.9955 0.9916 0.9921 0.9933
Diﬀusion exponent (n) 0.5159 0.5148 0.5816 0.5415
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than other formulations. As liquid parafﬁn content in HBS
capsules was increased, the drug release rate from these HBS
capsules was decreased more. Thus, liquid parafﬁn was the
best release modiﬁer amongst those excipients evaluated.
To analyze the mechanism of drug release from these HBS
capsules, the in vitro dissolution data were ﬁtted to various
mathematical models like zero order, ﬁrst order, Higuchi, and
Korsmeyer–Peppas models. The results of the curve ﬁtting into
these above-mentioned mathematical models are given in Table
3. The drug release pattern of these HBS capsules followed Hig-
uchi model (R2 = 0.9942–0.9962), and this was observed to be
closest to Korsmeyer–Peppas model (R2 = 0.9916–0.9955).
Again, the Korsmeyer–Peppas model has been employed in
the in vitro drug release behavior analysis of various pharmaceu-
tical formulations to distinguish between various competing re-
leasemechanisms: Fickian release (diffusion-controlled release),
non-Fickian release (anomalous transport), and case-II trans-
port (swelling-controlled release). When n takes the value 0.5
it indicates diffusion-controlled drug release and for the value
1.0 indicates swelling-controlled drug release. Values of n be-
tween 0.5 and 1.0 can be regarded as an indicator for both the
phenomena (anomalous transport). These extreme values for
the exponent n, 0.5 and 1.0, are only valid for slab geometryand for spheres and cylinders different values have been derived
(Blagoeva and Nedev, 2006). For a capsule, a cylindrical geom-
etry is considered for the determination of values of n for all
these HBS oﬂoxacin capsules. The values of n were within the
range of 0.5148–0.5816 indicating anomalous transport. This
could be attributed to the high water uptake by these capsule
matrixes leading to higher swelling of these capsules that
supported the anomalous release mechanism of oﬂoxacin
(Chavanpatil et al., 2006).
4. Conclusion
Gastroretentive HBS capsules of oﬂoxacin were prepared using
lactose, HPMC K4M and liquid parafﬁn. All these formulated
HBS capsules were ﬂoated well over 6 h with no ﬂoating lag
time. They also showed sustained drug release in 0.1 N HCl,
pH 1.2 over 6 h. Time for 50% release of oﬂoxacin was within
the range, 2.47 ± 0.02 to 3.27 ± 0.04 h. In addition, there were
signiﬁcant differences (p< 0.05) in the times for 50% release of
oﬂoxacin from all these HBS capsules. The in vitro drug release
from these HBS capsules was dependent on HPMCK4M, PVP
K 30, and liquid parafﬁn content. The drug release pattern of
theseHBS capsules containing oﬂoxacin followedHiguchimod-
el with the anomalous transport mechanism.
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